- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03781232
Non-invasive Glucose Measurement With Raman Technology in Patients With Type 1 and Type 2 Diabetes
Non-invasive Glucose Measurement With Raman Technology. Calibration of Newly Developed Devices in Patients With Type 1 and Type 2 Diabetes - Glucobrunn Study
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Subjects are recruited at two different sites.
Site 1: In group 1 subjects will on their regular stay in the clinic perform four measurement sessions a day. A measurement session consist of a reference capillary blood sample and two measures on the IMD.
Site 2: The study in group 2 consists of 26 home-based measurements and two in-clinic days. During the home measurements, 6 measurement sessions will be performed by the subjects a day. A measurement session consists of two reference BGMs, two reference CGMs and two measurements on the device. On in-clinic visits, subjects will be administered high glucose breakfast and the following 6-7 hours, measurement sessions are performed every 15 minutes.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Bad Heilbrunn, Tyskland, 83670
- m&i-Fachklinik Bad Heilbrunn - Zentrum für Diabetes und Stoffwechselerkrankungen
-
Ulm, Tyskland, 89081
- Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- At least 18 years of age
- Have a diagnosis of type 1 or type 2 diabetes mellitus (for RSP-09-02, only patients with type 1 diabetes)
- Skin phototype 1-4
- Be willing to perform a minimum of 6 / 12 (31 during excursion days) finger sticks per day during the study
- Be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol
- Be willing to provide written signed and dated informed consent
Exclusion Criteria:
- Inability to comply with the study procedures as described by the study protocol, according to the opinion of the investigator, due to e.g. known psychiatric diagnoses, lack of cognitive ability, alcohol dependency, drug use, psychosocial overload
- Have known severe allergy to medical grade adhesive or isopropyl alcohol used to clean the skin
- Be breastfeeding, pregnant, attempting to conceive or not willing and able to practice birth control during the study execution (applicable to female subjects only)
- Unable to hold hand/arm steadily (including tremors and Parkinson's Disease)
- Severe diabetes related complications such as advanced autonomic neuropathy, kidney disease, foot ulcers, legal blindness, or symptomatic cardiovascular disease as evidenced by a history of cardiovascular episode(s)
- Systemic or topical administration of glucocorticoids for the past 7 days
- Undergoing dialysis treatment
- Have extensive skin changes/diseases at the proposed measurement site (thenar) that could interfere with the accuracy of interstitial glucose measurements
- Have a concomitant medical condition which could interfere with the study devices (study arm 1: intake of acetaminophen study arm 2: intake of salicylic acid or higher doses of ascorbic acid)
- Unsuitable for participation due to any other cause as determined by the Investigator. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation e.g. with required documentation
- Dependency from the sponsor or the clinical investigator (e.g. co-workers of the sponsor, the study site, and/ or their families)
Additional exclusion criteria for study arm 2:
- Severe hypoglycemia resulting in seizure or loss of consciousness in the 3 months prior to enrollment
- Hypoglycemia unawareness
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: RSP-09-01
Enrolled subjects will perform 4 daily measurement session during their regular stay at the clinic.
A measurement session consists of a reference capillary blood sample and two measurements on the Prototype 0.3.
|
Prototype 0.3 is a non-invasive glucose monitoring device using Raman spectroscopy
|
Eksperimentell: RSP-09-02
Enrolled subjects will measure at home for 26 six days and visit the clinic two times.
During home measurements, 6 measurement sessions will be performed by the subject a day.
A measurement session consists of two BGMs, two CGMs and two measurements on the Prototype 0.3.
On in-clinic visits the subject will be administered a high glucose breakfast and the following 6-7 hours, measurement sessions will be performed every 15 minutes.
|
Prototype 0.3 is a non-invasive glucose monitoring device using Raman spectroscopy
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Generation and validation of predictive models by Inter Subject Unified Performance (ISUP).
Tidsramme: 2 years
|
Spectral Raman data will be collected together with paired reference measurements. Collected data will be used to generate calibration models capable of predicting tissue glucose levels. Models will be validated on independent data sets using the ISUP measure. |
2 years
|
Generation and validation of predictive models by Mean Absolute Relative Difference (MARD) measures
Tidsramme: 2 years
|
Spectral Raman data will be collected together with paired reference measurements. Collected data will be used to generate calibration models capable of predicting tissue glucose levels. Models will be validated on independent data sets using the MARD measure. |
2 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Guido Freckmann, Dr., Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- RSP-09
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Diabetes mellitus
-
Medical College of WisconsinMedical University of South CarolinaFullførtSukkersyke | Type 2 diabetes mellitus | Voksendiabetes mellitus | Ikke-insulinavhengig diabetes mellitus | Ikke-insulinavhengig diabetes mellitus, type IIForente stater
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.FullførtDiabetes mellitus, type 1 | Type 1 diabetes | Diabetes type 1 | Type 1 diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinavhengig | Juvenil-Debut Diabetes | Diabetes, autoimmun | Insulinavhengig diabetes mellitus 1 | Diabetes mellitus, insulinavhengig, 1 | Diabetes mellitus, sprø | Diabetes mellitus... og andre forholdForente stater
-
SanofiFullførtType 1 Diabetes Mellitus-Type 2 Diabetes MellitusUngarn, Den russiske føderasjonen, Tyskland, Polen, Japan, Forente stater, Finland
-
Meir Medical CenterFullførtDiabetes mellitus type 2 | Diabetes mellitus, ikke-insulinavhengig | Diabetes mellitus, om oral hypoglykemisk behandling | Voksen type diabetes mellitusIsrael
-
Peking Union Medical College HospitalUkjentType 2 diabetes mellitus | Type 1 diabetes mellitus | Svangerskapsdiabetes mellitus | Pankreatogen diabetes mellitus | Pregestasjonell diabetes mellitus | Diabetespasienter i perioperativ periodeKina
-
Guang NingRekrutteringType 2 diabetes mellitus | Type 1 diabetes mellitus | Monogenetisk diabetes | Pankreatogen diabetes | Legemiddelindusert diabetes mellitus | Andre former for diabetes mellitusKina
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and...Aktiv, ikke rekrutterendeDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinavhengig | Diabetes mellitus, ikke-insulinavhengigForente stater
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)FullførtDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinavhengig | Diabetes mellitus, ikke-insulinavhengigForente stater
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)FullførtDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinavhengig | Diabetes mellitus, ikke-insulinavhengigForente stater
-
Hoffmann-La RocheRoche DiagnosticsFullførtDiabetes mellitus type 2, diabetes mellitus type 1Tyskland
Kliniske studier på Prototype 0.3
-
Teva Branded Pharmaceutical Products R&D, Inc.FullførtTilbakefallende remitterende multippel sklerose
-
Universitaire Ziekenhuizen KU LeuvenAvsluttet
-
ANRS, Emerging Infectious DiseasesRekrutteringFriske voksneFrankrike, Sveits